Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151591 · ClinicalTrials.gov registry record · Phase 1
New Approaches to Smoking Cessation in Heavy Drinkers
A Phase 1 study of Nicotine Dependence and Cigarette Smoking, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02151591 is a Phase 1 study of Nicotine Dependence and Cigarette Smoking that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02151591, a Phase 1 study of Nicotine Dependence and Cigarette Smoking, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and test an integrated cognitive-behavioral intervention for smoking and alcohol among heavy drinking smokers. The current pre-pilot phase will be used to refine this protocol for the subsequent randomized, controlled pilot phase. The current study phase has two parts: 1) an intake session and brief physical; 2) a 12-week treatment phase in which participants receive varenicline (Chantix) and weekly, personalized counseling.
Conditions Studied
Interventions
- DRUG Varenicline
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02151591
The ClinicalTrials.gov registry entry for NCT02151591 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (86% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Nicotine Dependence appearing as the primary indexed condition, and to 1 intervention - of which Varenicline is the first listed.
NCT02151591 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02151591 about?
NCT02151591 is a clinical study titled "New Approaches to Smoking Cessation in Heavy Drinkers". The purpose of this study is to develop and test an integrated cognitive-behavioral intervention for smoking and alcohol among heavy drinking smokers. The current pre-pilot phase will be used to refine this protocol for the subsequent randomized, controlled pilot phase. The current study phase has t...
What is the current status of trial NCT02151591?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-03-01. Estimated completion is 2018-08-01.
What conditions does trial NCT02151591 study?
This clinical trial studies the following conditions: Nicotine Dependence, Cigarette Smoking, Alcohol Consumption, Heavy Drinking.
What interventions are being tested in trial NCT02151591?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT02151591?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02151591 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
RECRUITING · Phase 1
-
Brain Reaction to Treatment of Nicotine Dependence
COMPLETED · Phase 1
-
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
COMPLETED · Phase 1
-
Nicotine Differences in Smokers
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.